Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Study Overview
=================
Brief Summary
-----------------
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

Detailed Description
-----------------
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.

Official Title
-----------------
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Conditions
-----------------
Interstitial Lung Disease

Intervention / Treatment
-----------------
* Other: ILD
* Other: Healthy
* Other: Pneumonia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia Patients willing to provide written informed consent Exclusion Criteria: Unwillingness/unable to give blood samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ILD<br>250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis. | Other: ILD<br>* 100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis<br>|
| Healthy<br>100 healthy participants as a control group. | Other: Healthy<br>* 100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.<br>|
| Pneumonia<br>25 patients with pneumonia as a control group. | Other: Pneumonia<br>* 100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Future Disease Management | Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease. | 1 visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ILD